Synapse Open Synapse
Biology

STAT+: A German biotech has big ambitions in cancer. Now it needs to get a medicine approved

STAT News · · 1 min read

After a quarter century of work, the German biotech Immatics is facing a pivotal moment as it awaits Phase 3 results for its lead candidate in melanoma.

Latest from STAT News